Back

The lung employs an intrinsic surfactant-mediated inflammatory response for viral defense

Leibel, S. L.; McVicar, R. N.; Murad, R.; Kwong, E. M.; Clark, A. E.; Alvarado, A.; Grimmig, B. A.; Nuryyev, R.; Young, R. E.; Lee, J. C.; Peng, W.; Zhu, Y. P.; Griffis, E.; Nowell, C. J.; James, B.; Alarcon, S.; Malhotra, A.; Gearing, L. J.; Hertzog, P. J.; Galapate, C. M.; Galenkamp, K. M. O.; Commisso, C.; Smith, D. M.; Sun, X.; Carlin, A. F.; Croker, B. A.; Snyder, E. Y.

2023-01-27 immunology
10.1101/2023.01.26.525578 bioRxiv
Show abstract

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) causes an acute respiratory distress syndrome (ARDS) that resembles surfactant deficient RDS. Using a novel multi-cell type, human induced pluripotent stem cell (hiPSC)-derived lung organoid (LO) system, validated against primary lung cells, we found that inflammatory cytokine/chemokine production and interferon (IFN) responses are dynamically regulated autonomously within the lung following SARS-CoV-2 infection, an intrinsic defense mechanism mediated by surfactant proteins (SP). Single cell RNA sequencing revealed broad infectability of most lung cell types through canonical (ACE2) and non-canonical (endocytotic) viral entry routes. SARS-CoV-2 triggers rapid apoptosis, impairing viral dissemination. In the absence of surfactant protein B (SP-B), resistance to infection was impaired and cytokine/chemokine production and IFN responses were modulated. Exogenous surfactant, recombinant SP-B, or genomic correction of the SP-B deletion restored resistance to SARS-CoV-2 and improved viability.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.